Acute disseminated fatal toxoplasmosis after haploidentical stem cell transplantation despite atovaquone prophylaxis in a young man

Pediatric Infectious Disease Journal

Volumn 29, Issue 11, 2010, Pages 1059-1060

  Garcia De La Fuente, Isabel ^a   Ansari, Marc ^a   Rougemont, Anne Laure ^a   Passweg, Jakob R ^a   Gumy Pause, Fabienne ^a   Ozsahin, Hulya ^a   Lobrinus, Johannes A ^a   Posfay Barbe, Klara M ^a  

^a GENEVA UNIVERSITY HOSPITALS   (Switzerland)

Author keywords

atovaquone; Disseminated; prophylaxis; stem cell transplantation; toxoplasmosis

Indexed keywords

ALEMTUZUMAB; AMPHOTERICIN B LIPID COMPLEX; ATOVAQUONE; C REACTIVE PROTEIN; CLOFARABINE; COTRIMOXAZOLE; CYCLOPHOSPHAMIDE; CYTARABINE; ETOPOSIDE; GANCICLOVIR; MEROPENEM; STEROID; THYMOCYTE ANTIBODY; VALGANCICLOVIR; VANCOMYCIN; VORICONAZOLE;

ACIDOSIS; ACUTE LYMPHOBLASTIC LEUKEMIA; ADULT; ADULT RESPIRATORY DISTRESS SYNDROME; ARTICLE; ARTIFICIAL VENTILATION; AUTOPSY; BLOOD CULTURE; CANCER COMBINATION CHEMOTHERAPY; CASE REPORT; CYTOMEGALOVIRUS INFECTION; DISEASE SEVERITY; DRUG MEGADOSE; DRUG SUBSTITUTION; DRUG WITHDRAWAL; FEVER; GRAFT VERSUS HOST REACTION; HAPLOIDENTICAL HEMATOPOIETIC STEM CELL TRANSPLANTATION; HEART FAILURE; HEMATOPOIETIC STEM CELL TRANSPLANTATION; HUMAN; HYPOTENSION; IMMUNOHISTOCHEMISTRY; INFECTION PREVENTION; INTENSIVE CARE UNIT; KIDNEY FAILURE; LUNG ASPERGILLOSIS; MACULOPAPULAR RASH; MALE; MULTIPLE ORGAN FAILURE; PANCYTOPENIA; PATIENT MONITORING; PERICARDIAL EFFUSION; PNEUMOCYSTIS PNEUMONIA; POLYMERASE CHAIN REACTION; PRIORITY JOURNAL; REMISSION; TOXOPLASMOSIS; URINE CULTURE; VIRUS PNEUMONIA; WEIGHT REDUCTION; WHOLE BODY RADIATION;

EID: 78149279869     PISSN: 08913668     EISSN: 15320987     Source Type: Journal    
DOI: 10.1097/INF.0b013e3181f30eb6     Document Type: Article

References (10)

1. Slavin MA, Meyers JD, Remington JS, et al. Toxoplasma gondii infection in marrow transplant recipients: a 20 year experience. Bone Marrow Transplant. 1994;13:549-557.
2. Mofenson LM, Oleske J, Serchuck L, et al. CDC; National Institutes of Health; Infectious Diseases Society of America. Treating opportunistic infections among HIV-exposed and infected children: recommendations from CDC, the national institutes of health, and the infectious diseases society of America. MMWR Morb Mortal Wkly Rep Recomm Rep. 2004;53(RR-14): 1-92.
3. Derouin F, Pelloux H; ESCMID Study Group on Clinical Parasitology. Prevention of toxoplasmosis in transplant patients. Clin Microbiol Infect. 2008;14:1089-1101.
4. Fricker-Hidalgo H, Bulabois CE, Brenier-Pinchart MP, et al. Diagnosis of toxoplasmosis after allogeneic stem cell transplantation: results of DNA detection and serological techniques. Clin Infect Dis. 2009;48: e9-e15.
5. Foudrinier F, Aubert D, Puygauthier-Toubas D, et al. Detection of Toxoplasma gondii in immunodeficient subjects by gene amplification: influence of therapeutics. Scand J Infect Dis. 1996;28:383-386.
6. Bretagne S, Costa JM, Foulet F, et al. Prospective study of toxoplasma reactivation by polymerase chain reaction in allogeneic stem-cell transplant recipients. Transpl Infect Dis. 2000;2:127-132.
7. Spencer CM, Goa KL. Atovaquone. A review of its pharmacological properties and therapeutic efficacy in opportunistic infections. Drugs. 1995;50:176-196.
8. Pearson PA, Piracha AR, Sen HA, et al. Atovaquone for the treatment of toxoplasma retinochoroiditis in immunocompetent patients. Ophthalmology. 1999;106:148-153.
9. El-Sadr WM, Murphy RL, Yurik TM, et al. Community Program for Clinical Research on AIDS; The AIDS Clinical Trials Group. Atovaquone compared with dapsone for the prevention of Pneumocystis carinii pneumonia in patients with HIV infection who cannot tolerate trimethoprim, sulfonamides, or both. N Engl J Med. 1998;339:1889-1895.
10. Megged O, Shalit I, Yaniv I, et al. Breakthrough cerebral toxoplasmosis in a patient receiving atovaquone prophylaxis after a hematopoietic stem cell transplantation. Pediatr Transplant. 2008;12:902-905.